UAV Stock Overview
Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Oragenics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.60 |
| 52 Week High | US$22.92 |
| 52 Week Low | US$5.93 |
| Beta | 0.36 |
| 1 Month Change | 0% |
| 3 Month Change | -9.89% |
| 1 Year Change | -62.84% |
| 3 Year Change | -63.47% |
| 5 Year Change | -90.34% |
| Change since IPO | -99.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| UAV | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -3.1% | 1.8% |
| 1Y | -62.8% | -22.4% | 2.2% |
Return vs Industry: UAV underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: UAV underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| UAV volatility | |
|---|---|
| UAV Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: UAV has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine UAV's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 5 | Kim Murphy | www.oragenics.com |
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company’s product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries.
Oragenics, Inc. Fundamentals Summary
| UAV fundamental statistics | |
|---|---|
| Market cap | €5.81m |
| Earnings (TTM) | -€13.02m |
| Revenue (TTM) | €119.88k |
48.5x
P/S Ratio-0.4x
P/E RatioIs UAV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UAV income statement (TTM) | |
|---|---|
| Revenue | US$131.52k |
| Cost of Revenue | US$0 |
| Gross Profit | US$131.52k |
| Other Expenses | US$14.42m |
| Earnings | -US$14.29m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.29 |
| Gross Margin | 100.00% |
| Net Profit Margin | -10,863.96% |
| Debt/Equity Ratio | 2.1% |
How did UAV perform over the long term?
See historical performance and comparison